L P Voruganti
Affiliation: McMaster University
- Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) studyL P Voruganti
Department of Psychiatry and Behavioural Neurosciences, 100 West 5th Street, Hamilton, Ontario Canada L8N 3K7
Schizophr Res 96:215-22. 2007..Discerning the modifiable risk factors is crucial for developing diabetes prevention strategies in schizophrenia...
- Brain imaging research on subjective responses to psychotropic drugsL P Voruganti
McMaster University, Hamilton, ON, Canada
Acta Psychiatr Scand Suppl . 2005..Neuroimaging studies on subjective responses to psychotropic drugs in humans were reviewed to examine progress in the field and identify gaps in knowledge...
- New generation antipsychotic drugs and compliance behaviourLakshmi P Voruganti
McMaster University, Hamilton, Ontario, Canada
Curr Opin Psychiatry 21:133-9. 2008....
- Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapineL P Voruganti
McMaster University, Canada
Schizophr Res 96:146-55. 2007..Cognitive deficits are recognized as a critical determinant of functional outcomes in schizophrenia; and second generation antipsychotic drugs have been touted for their potential to enhance cognitive functioning and community tenure...
- Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia--findings from an in vivo SPECT studyLakshmi N P Voruganti
Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, and Humber River Regional Hospital, Toronto, Ontario, Canada
Schizophr Res 88:179-86. 2006....
- Impact of atypical antipsychotics on quality of life in patients with schizophreniaA George Awad
Institute of Medical Science and Department of Psychiatry, University of Toronto, Humber River Regional Hospital, Toronto, Ontario, Canada
CNS Drugs 18:877-93. 2004....
- Going beyond: an adventure- and recreation-based group intervention promotes well-being and weight loss in schizophreniaLakshmi N P Voruganti
St Joseph s Healthcare, Hamilton, Ontario
Can J Psychiatry 51:575-80. 2006..To undertake a preliminary study to assess the feasibility of clinical implementation and evaluate the effectiveness of a novel adventure- and recreation-based group intervention in the rehabilitation of individuals with schizophrenia...
- Personal evaluation of transitions in treatment (PETiT):a scale to measure subjective aspects of antipsychotic drug therapy in schizophreniaLakshmi N P Voruganti
Institute of Medical Science, University of Toronto, Toronto, Canada
Schizophr Res 56:37-46. 2002....
- The burden of schizophrenia on caregivers: a reviewA George Awad
Department of Psychiatry and the Institute of Medical Science, University of Toronto, Humber River Regional Hospital, Toronto, Ontario, M6M 3Z4, Canada
Pharmacoeconomics 26:149-62. 2008....
- New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?A George Awad
University of Toronto, Institute of Medical Science, Ontario
Can J Psychiatry 49:297-302. 2004..This overview reviews the impact of second-generation antipsychotics on less frequently researched outcomes such as medication-adherence behaviour, quality of life, and subjective tolerability in patients with schizophrenia...
- Body weight, image and self-esteem evaluation questionnaire: development and validation of a new scaleA George Awad
Department of Psychiatry, Humber Regional Hospital, 1575 Keele Street, Toronto M6M 3Z4, Canada
Schizophr Res 70:63-7. 2004....
- What's in a name? The evolution of the nomenclature of antipsychotic drugsCaroline King
Department of Psychiatry, University of Western Ontario, London, Ont
J Psychiatry Neurosci 27:168-75. 2002..This article examines the origins, progenitors and usage of the word "antipsychotic" and explores its ramifications...